Distinguished in Prostate Cancer

Eli Rosenbaum

Petah Tiqwa, M, IL 
Distinguished in Prostate Cancer
Petah Tiqwa, M, IL 
OverviewLocationsClinical Research

Overview

Eli Rosenbaum practices in Petah Tiqwa, Israel. Mr. Rosenbaum is rated as a Distinguished expert by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Prostate Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, and Prostatectomy.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 22 articles and participated in 2 clinical trials in the study of Prostate Cancer.

Gender
Male

Locations

Petah Tiqwa, M, Israel
Other Locations
Petach Tikvah, Israel
Tel Aviv, TA, Israel
Ramat Gan, TA, Israel
Ramat Aviv, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Enrollment Status: Completed
Publish Date: June 12, 2019
Intervention Type: Device, Drug
Study Phase: Phase 4
View 1 Less Clinical Trial

48 Total Publications

Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.
Challenges in Interpreting Survival Metrics in Clinical Trials: The Utility of Restricted Mean Survival Analyses.
Journal: International journal of radiation oncology, biology, physics
Published: January 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rosenbaum's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile